Dick de Zeeuw
Dick de Zeeuw
Professor Clinical Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
Verified email at umcg.nl
Title
Cited by
Cited by
Year
Executive summary: heart disease and stroke statistics—2015 update: a report from the American Heart Association
D Mozaffarian, EJ Benjamin, AS Go, DK Arnett, MJ Blaha, M Cushman, ...
Circulation 131 (4), 434-441, 2015
34378*2015
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy
BM Brenner, ME Cooper, D De Zeeuw, WF Keane, WE Mitch, HH Parving, ...
New England journal of medicine 345 (12), 861-869, 2001
79372001
Canagliflozin and cardiovascular and renal events in type 2 diabetes
B Neal, V Perkovic, KW Mahaffey, D De Zeeuw, G Fulcher, N Erondu, ...
New England Journal of Medicine 377 (7), 644-657, 2017
29992017
The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo …
C Baigent, MJ Landray, C Reith, J Emberson, DC Wheeler, C Tomson, ...
The Lancet 377 (9784), 2181-2192, 2011
21692011
The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo …
C Baigent, MJ Landray, C Reith, J Emberson, DC Wheeler, C Tomson, ...
The Lancet 377 (9784), 2181-2192, 2011
21692011
Heart disease and stroke statistics: 2006 update
American Heart Association
http://circ. ahajournals. org/cgi/reprint/CIRCULATIONAHA. 105.171600 v1, 2006
20312006
A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease
MA Pfeffer, EA Burdmann, CY Chen, ME Cooper, D De Zeeuw, ...
New England Journal of Medicine 361 (21), 2019-2032, 2009
18572009
Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population
HL Hillege, V Fidler, GFH Diercks, WH van Gilst, D de Zeeuw, ...
Circulation 106 (14), 1777-1782, 2002
15662002
Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis
TH Jafar, PC Stark, CH Schmid, M Landa, G Maschio, PE De Jong, ...
Annals of internal medicine 139 (4), 244-252, 2003
12432003
Cardiorenal end points in a trial of aliskiren for type 2 diabetes
HH Parving, BM Brenner, JJV McMurray, D De Zeeuw, SM Haffner, ...
New England Journal of Medicine 367 (23), 2204-2213, 2012
12142012
Renal function, neurohormonal activation, and survival in patients with chronic heart failure
HL Hillege, ARJ Girbes, PJ De Kam, F Boomsma, D De Zeeuw, ...
Circulation 102 (2), 203-210, 2000
12132000
Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease: a meta-analysis of patient-level data
TH Jafar, CH Schmid, M Landa, I Giatras, R Toto, G Remuzzi, G Maschio, ...
Annals of internal medicine 135 (2), 73-87, 2001
11392001
Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement
EL Knight, JC Verhave, D Spiegelman, HL Hillege, D De Zeeuw, ...
Kidney international 65 (4), 1416-1421, 2004
10622004
Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL
D De Zeeuw, G Remuzzi, HH Parving, WF Keane, Z Zhang, S Shahinfar, ...
Kidney international 65 (6), 2309-2320, 2004
10342004
Renal function as a predictor of outcome in a broad spectrum of patients with heart failure
HL Hillege, D Nitsch, MA Pfeffer, K Swedberg, JJV McMurray, S Yusuf, ...
Circulation 113 (5), 671-678, 2006
9432006
Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy
D De Zeeuw, G Remuzzi, HH Parving, WF Keane, Z Zhang, S Shahinfar, ...
Circulation 110 (8), 921-927, 2004
8862004
Canagliflozin and renal outcomes in type 2 diabetes and nephropathy
V Perkovic, MJ Jardine, B Neal, S Bompoint, HJL Heerspink, ...
New England Journal of Medicine 380 (24), 2295-2306, 2019
8782019
Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity
HL Hillege, WMT Janssen, AAA Bak, GFH Diercks, DE Grobbee, H Crijns, ...
Journal of internal medicine 249 (6), 519-526, 2001
7802001
Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial
D De Zeeuw, R Agarwal, M Amdahl, P Audhya, D Coyne, T Garimella, ...
The Lancet 376 (9752), 1543-1551, 2010
7412010
Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease
D De Zeeuw, T Akizawa, P Audhya, GL Bakris, M Chin, H Christ-Schmidt, ...
New England Journal of Medicine 369 (26), 2492-2503, 2013
6372013
The system can't perform the operation now. Try again later.
Articles 1–20